VEGF165b突变体作为免疫佐剂增强抗肿瘤免疫应答
该研究在小鼠乳腺癌模型中,将mVEGF165b与基于MUC1肽的癌症疫苗共免疫,评估其作为免疫佐剂的效果。结果显示VEGF抗体滴度升高约600,000倍,调节性T细胞频率降低,MUC-1特异性IFN-γ阳性CD8+ T细胞和抗MUC1体液应答显著增加,联合免疫产生更优的抗肿瘤反应并显著延长荷瘤小鼠生存期。
要点
- mVEGF165b与MUC1肽疫苗共免疫使小鼠VEGF抗体滴度升高约600,000倍。
- 共免疫降低预防和治疗场景下调节性T细胞频率。
- 联合免疫增强MUC-1特异性CD8+ T细胞和体液应答并延长生存期。
核心结论
- mVEGF165b可能作为理想免疫佐剂,通过克服免疫耐受增强肽基肿瘤疫苗的免疫疗效。
研究设计与样本
- 在小鼠乳腺癌模型中,将mVEGF165b与基于MUC1的肽癌症疫苗共免疫,评估免疫应答和抗肿瘤效果。
主要发现
- 共免疫mVEGF165b与MUC1肽疫苗后,小鼠VEGF抗体滴度增加约600,000倍。
- 抗VEGF抗体在预防和治疗场景下均降低调节性T细胞频率。
- Tregs减少与MUC-1特异性IFN-γ产生CD8+ T细胞和抗MUC1体液应答显著增加相关。
- 联合共免疫产生更优的抗肿瘤反应并显著延长荷瘤小鼠生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Compelling evidence has shown that blocking VEGF via monoclonal antibodies may be beneficial in that it not only inhibits tumor angiogenesis but also reduces immune suppression and promotes T cell infiltration into tumors. Herein, we determined whether our recently generated VEGF165b mutant could be used as a co-immunization adjunct to augment the peptide cancer-vaccine- induced immune response in a mouse model of breast cancer. When co-immunized mVEGF165b with the peptide-based cancer vaccine (MUC1, a T-cell epitope dominant peptide vaccine from Mucin1), the VEGF antibody titers increased approximately 600,000-fold in mice. Moreover, the anti-VEGF antibody also reduced the frequency of regulatory T cells (Tregs) in both preventive and therapeutic scenarios. Mechanistically, the decrease of the Tregs population was associated with a remarkably increased MUC-1-specific IFN-γ-producing CD8+ T cells and anti-MUC1 humoral response. Finally, this combination co-immunization produced a superior antitumor response and significantly prolonged survival of tumor-bearing mice. In conclusion, our findings suggest that mVEGF165b may be an ideal immunization adjunct to enhance the immune efficacy of peptide-based tumor vaccines by overcoming immune tolerance.
引用
- Zhang H, Jia E, Xia W, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019. PMID: 30837171. doi:10.1016/j.vaccine.2019.02.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。